The Glivec patent expires in most countries latest on 21 Dec 2016.

The CML Advocates Network has been following the situation of TKI generics closely for 3 years, and has now provided a webinar which summarizes the current status.

This webinar answers some important questions, such as:

  • What are generics, and do they differentiate from innovator products?
  • Which generics of CML Tyrosine Kinase Inhibitors exist?
  • What do we know about efficacy and safety?
  • What information on CML generics is available to patients?
  • What has the patient advocacy community done so far?
  • What can patients and patient advocacy groups do about CML generics?

More can be found on our CML Advocates Network Knowledge Base on CML Generics at

If you want access to the slides, please contact Jan Geissler at .

Webstream via AuthorStream (allows to skip slides)










Olga Lucia Jimenez Community Builder Avatar   15.12.2016 (12:20:48)
Generic drugs for cml Yes No Would like to have access to the webinar

Please donate!

Please donate!


Tweet Feed

@SamanthaNier More than 300 responses in one week and we keep on working to get many more until July (: We are real……

Wednesday, 21 March 2018 in reply to SamanthaNier

Participa en la encuesta si estás en remisión libre de tratamiento. @Aelemic #cml #lmc #TFR…

Retweeted Wednesday, 21 March 2018

Why are we launching a Treatment-Free Remission survey?Because the patient community feels #TFR also needs careful,……

Wednesday, 21 March 2018